Given that the PD-1/PD-L1 pathway in the tumor microenvironment may induce suppression of the immune system, PD-L1 expression has been investigated as a predictive biomarker for anti-PD1/PD-L1 therapy. This evidence concerns the gene PDCD1 and neoplasm.